Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 12/20 | 1.00 |
| ▸ | CCNA2 | P20248 | 8/20 | 1.00 |
| ▸ | CCNA1 | P78396 | 8/20 | 1.00 |
| ▸ | CDK4 | P11802 | 7/20 | 1.00 |
| ▸ | GSK3B | P49841 | 6/20 | 1.00 |
| ▸ | CCND3 | P30281 | 4/20 | 1.00 |
| ▸ | PIM1 | P11309 | 3/20 | 1.00 |
| ▸ | SLC2A1 | P11166 | 2/20 | 1.00 |
| ▸ | MTOR | P42345 | 2/20 | 1.00 |
| ▸ | AURKA | O14965 | 1/20 | 1.00 |
| ▸ | CCNK | O75909 | 1/20 | 1.00 |
| ▸ | CDK12 | Q9NYV4 | 1/20 | 1.00 |
| ▸ | KDR | P35968 | 1/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17214696 | 0.90 | CDK2 (0.81) | CDK2CCNA2CCNA1CDK4GSK3B | |
| SCHEMBL4478489 | 0.88 | SLC2A1 (0.83) | CDK2CCNA2CCNA1CDK4GSK3B | |
| SCHEMBL4480544 | 0.88 | SLC2A1 (1.00) | CDK2CCNA2CCNA1CDK4GSK3B | |
| SCHEMBL4483262 | 0.83 | CDK4 (1.00) | CDK2CCNA2CCNA1CDK4GSK3B | |
| SCHEMBL25068526 | 0.82 | CCNA2 (1.00) | CDK2CCNA2CCNA1CDK4GSK3B | |
| SCHEMBL4475712 | 0.82 | CDK2 (1.00) | CDK2CCNA2CCNA1CDK4GSK3B | |
| SCHEMBL25068533 | 0.81 | CDK4 (0.76) | CDK2CCNA2CCNA1CDK4GSK3B | |
| SCHEMBL25068536 | 0.81 | CDK4 (1.00) | CDK2CCNA2CCNA1CDK4GSK3B | |
| SCHEMBL25068498 | 0.80 | CCNA2 (0.85) | CDK2CCNA2CCNA1CDK4GSK3B | |
| SCHEMBL25068538 | 0.80 | CCNA2 (0.83) | CDK2CCNA2CCNA1CDK4GSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7279473-B2 | Pyrazolopyridazine derivatives | SMITHKLINE BEECHAM CORPORATION (US) | 2007-10-09 | — | — | US | claimed |
| EP-1463730-B1 | PYRAZOLOPYRIDAZINE DERIVATIVES | SMITHKLINE BEECHAM CORP (US) | 2006-04-19 | — | — | EP | claimed |
| US-20060069097-A1 | Pyradazine compounds as gsk-3 inhibitors | SMITHKLINE BEECHAM CORPORATION | 2006-03-30 | — | — | US | claimed |
| EP-1551842-A1 | PYRADAZINE COMPOUNDS AS GSK-3 INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2005-07-13 | — | — | EP | claimed |
| US-20050090507-A1 | Pyrazolopyridazine derivatves | SMITHKLINE BEECHAM CORPORATION | 2005-04-28 | — | — | US | claimed |
| WO-2004035588-A1 | PYRADAZINE COMPOUNDS AS GSK-3 INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2004-04-29 | — | — | WO | claimed |
| US-11820753-B2 | Inhibitors of bacterial pasta kinases | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2023-11-21 | — | — | US | disclosed |
| US-11596631-B2 | CDK12 inhibitors and their uses | THE UNIVERSITY OF NOTTINGHAM (GB) | 2023-03-07 | — | — | US | disclosed |
| US-20230060122-A9 | INHIBITORS OF BACTERIAL PASTA KINASES | WISCONSIN ALUMNI RESEARCH FOUNDATION | 2023-02-23 | — | — | US | disclosed |
| US-20220281930-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PATHOLOGICAL PAIN AND ITCH | DUKE UNIVERSITY (US) | 2022-09-08 | — | — | US | disclosed |
| US-20220251062-A1 | INHIBITORS OF BACTERIAL PASTA KINASES | WISCONSIN ALUMNI RES FOUND (US) | 2022-08-11 | — | — | US | disclosed |
| US-11406643-B2 | Targeting kinases for the treatment of cancer metastasis | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2022-08-09 | — | — | US | disclosed |
| EP-4036583-A1 | TARGETING KINASES FOR THE TREATMENT OF CANCER METASTASIS | Board of Regents, The University of Texas System (US) | 2022-08-03 | — | — | EP | disclosed |
| EP-1463730-B1 | PYRAZOLOPYRIDAZINE DERIVATIVES | SMITHKLINE BEECHAM CORP (US) | 2006-04-19 | — | — | EP | disclosed |
| US-20060069097-A1 | Pyradazine compounds as gsk-3 inhibitors | SMITHKLINE BEECHAM CORPORATION | 2006-03-30 | — | — | US | disclosed |
| EP-1551842-A1 | PYRADAZINE COMPOUNDS AS GSK-3 INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2005-07-13 | — | — | EP | disclosed |
| US-20050090507-A1 | Pyrazolopyridazine derivatves | SMITHKLINE BEECHAM CORPORATION | 2005-04-28 | — | — | US | disclosed |
| EP-1463730-A1 | PYRAZOLOPARIDAZINE DERIVATIVES | SmithKline Beecham Corporation (US) | 2004-10-06 | — | — | EP | disclosed |
| WO-2004035588-A1 | PYRADAZINE COMPOUNDS AS GSK-3 INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2004-04-29 | — | — | WO | disclosed |
| WO-2003051886-A1 | PYRAZOLOPYRIDAZINE DERIVATIVES | SMITHKLINE BEECHAM CORPORATION (US) | 2003-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11820753-B2 | Inhibitors of bacterial pasta kinases | SBK3, MAP3K3, MAP4K3 | CDK2 148/4885CCNA2 579/4885CCNA1 718/4885 |
| US-20050090507-A1 | Pyrazolopyridazine derivatves | CDK4, CDK3, CDK8 | CDK2 8/4885CCNA2 34/4885CCNA1 36/4885 |
| US-11596631-B2 | CDK12 inhibitors and their uses | CDK12, CDK1, CDK17 | CDK2 13/4885CCNA2 16/4885CCNA1 37/4885 |
| US-20220251062-A1 | INHIBITORS OF BACTERIAL PASTA KINASES | MAP3K3, MAP4K3, SBK3 | CDK2 186/4885CCNA2 633/4885CCNA1 711/4885 |
| US-20230060122-A9 | INHIBITORS OF BACTERIAL PASTA KINASES | SBK3, MAP3K3, MAP4K3 | CDK2 148/4885CCNA2 579/4885CCNA1 718/4885 |
| US-20060069097-A1 | Pyradazine compounds as gsk-3 inhibitors | GSK3B, GSK3A, GSKIP | CDK2 91/4885CCNA2 2614/4885CCNA1 1876/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.